{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T00:06:39Z","timestamp":1752537999526,"version":"3.41.2"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,7,14]]},"DOI":"10.7759\/cureus.87898","type":"journal-article","created":{"date-parts":[[2025,7,14]],"date-time":"2025-07-14T14:24:21Z","timestamp":1752503061000},"source":"Crossref","is-referenced-by-count":0,"title":["A Case of Complex Regional Pain Syndrome With Hypermobile Ehlers-Danlos Syndrome and Mast Cell Activation Syndrome: The Role of Unconventional Therapies"],"prefix":"10.7759","author":[{"given":"Zian","family":"Shabbir","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Layla","family":"Mazdeyasnan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mary","family":"McLain","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.h2730","article-title":"Complex regional pain syndrome","volume":"351","author":"Bruehl S","year":"2015","unstructured":"Bruehl S. Complex regional pain syndrome. BMJ. 2015, 351:h2730. 10.1136\/bmj.h2730","journal-title":"BMJ"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.4236\/nm.2012.33027","article-title":"Systemic complications of complex regional pain syndrome","volume":"13","author":"Schwartzman RJ","year":"2013","unstructured":"Schwartzman RJ. Systemic complications of complex regional pain syndrome. Neurosci Med. 2013, 13:225-42. 10.4236\/nm.2012.33027","journal-title":"Neurosci Med"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1002\/ajmg.c.31538","article-title":"Hypermobile Ehlers-Danlos syndrome (a.k.a. Ehlers-Danlos syndrome type III and Ehlers-Danlos syndrome hypermobility type): clinical description and natural history","volume":"175","author":"Tinkle B","year":"2017","unstructured":"Tinkle B, Castori M, Berglund B, Cohen H, Grahame R, Kazkaz H, Levy H. Hypermobile Ehlers-Danlos syndrome (a.k.a. Ehlers-Danlos syndrome type III and Ehlers-Danlos syndrome hypermobility type): clinical description and natural history. Am J Med Genet C Semin Med Genet. 2017, 175:48-69. 10.1002\/ajmg.c.31538","journal-title":"Am J Med Genet C Semin Med Genet"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1007\/s11481-013-9451-y","article-title":"Treatment of complex regional pain syndrome (CRPS) using low dose naltrexone (LDN)","volume":"8","author":"Chopra P","year":"2013","unstructured":"Chopra P, Cooper MS. Treatment of complex regional pain syndrome (CRPS) using low dose naltrexone (LDN). J Neuroimmune Pharmacol. 2013, 8:470-6. 10.1007\/s11481-013-9451-y","journal-title":"J Neuroimmune Pharmacol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.molimm.2014.03.001","article-title":"Mast cells: versatile gatekeepers of pain","volume":"63","author":"Chatterjea D","year":"2014","unstructured":"Chatterjea D, Martinov T. Mast cells: versatile gatekeepers of pain. Mol Immunol. 2014, 63:38-44. 10.1016\/j.molimm.2014.03.001","journal-title":"Mol Immunol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.3390\/jpm13111562","article-title":"Neuropsychiatric manifestations of mast cell activation syndrome and response to mast-cell-directed treatment: a case series","volume":"13","author":"Weinstock LB","year":"2023","unstructured":"Weinstock LB, Nelson RM, Blitshteyn S. Neuropsychiatric manifestations of mast cell activation syndrome and response to mast-cell-directed treatment: a case series. J Pers Med. 2023, 13:1562. 10.3390\/jpm13111562","journal-title":"J Pers Med"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-019-04293-w","article-title":"Pain and gastrointestinal dysfunction are significant associations with psychiatric disorders in patients with Ehlers-Danlos syndrome and hypermobility spectrum disorders: a retrospective study","volume":"39","author":"Wasim S","year":"2019","unstructured":"Wasim S, Suddaby JS, Parikh M, Leylachian S, Ho B, Guerin A, So J. Pain and gastrointestinal dysfunction are significant associations with psychiatric disorders in patients with Ehlers-Danlos syndrome and hypermobility spectrum disorders: a retrospective study. Rheumatol Int. 2019, 39:1241-8. 10.1007\/s00296-019-04293-w","journal-title":"Rheumatol Int"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1097\/ALN.0b013e31824bb303","article-title":"Substance P signaling controls mast cell activation, degranulation, and nociceptive sensitization in a rat fracture model of complex regional pain syndrome","volume":"116","author":"Li WW","year":"2012","unstructured":"Li WW, Guo TZ, Liang DY, Sun Y, Kingery WS, Clark JD. Substance P signaling controls mast cell activation, degranulation, and nociceptive sensitization in a rat fracture model of complex regional pain syndrome. Anesthesiology. 2012, 116:882-95. 10.1097\/ALN.0b013e31824bb303","journal-title":"Anesthesiology"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.5435\/JAAOSGlobal-D-17-00088","article-title":"Validation of digital Visual Analog Scale pain scoring with a traditional paper-based Visual Analog Scale in adults","volume":"2","author":"Delgado DA","year":"2018","unstructured":"Delgado DA, Lambert BS, Boutris N, McCulloch PC, Robbins AB, Moreno MR, Harris JD. Validation of digital Visual Analog Scale pain scoring with a traditional paper-based Visual Analog Scale in adults. J Am Acad Orthop Surg Glob Res Rev. 2018, 2:e088. 10.5435\/JAAOSGlobal-D-17-00088","journal-title":"J Am Acad Orthop Surg Glob Res Rev"},{"key":"ref10","doi-asserted-by":"crossref","DOI":"10.1136\/annrheumdis-2024-eular.4994","article-title":"Pos1149 hypermobility spectrum disorders in severe chronic pain syndromes: evaluating the performance of Beighton score versus clinical assessment","volume":"83","author":"Ming-Azevedo P","year":"2024","unstructured":"Ming-Azevedo P, Mettler J, H\u00fcgle T. Pos1149 hypermobility spectrum disorders in severe chronic pain syndromes: evaluating the performance of Beighton score versus clinical assessment. Ann Rheum Dis. 2024, 83:580-1.","journal-title":"Ann Rheum Dis"},{"key":"ref11","unstructured":"The Ehlers-Danlos Society. Diagnostic criteria for Hypermobile Ehlers-Danlos syndrome. (2024). Accessed. October 10, 2024: https:\/\/www.ehlers-danlos.com\/wp-content\/uploads\/2019\/09\/hEDS-Dx-Criteria-checklist-1-Fillable-form.pdf."},{"key":"ref12","unstructured":"Everything is connected to everything. A clinician guide from the Everything is Connected to Everything Project. (2023). Accessed: August 15, 2023: https:\/\/allbrainsbelong.org\/wp-content\/uploads\/2023\/08\/CLINICIAN-GUIDE-Everything-is-Connected-to-Everything-Project-...."},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1007\/s00210-016-1247-1","article-title":"Pharmacological treatment options for mast cell activation disease","volume":"389","author":"Molderings GJ","year":"2016","unstructured":"Molderings GJ, Haenisch B, Brettner S, et al.. Pharmacological treatment options for mast cell activation disease. Naunyn Schmiedebergs Arch Pharmacol. 2016, 389:671-94. 10.1007\/s00210-016-1247-1","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.3390\/ph15091039","article-title":"Leukotrienes vs. montelukast\u2014activity, metabolism, and toxicity hints for repurposing","volume":"15","author":"Marques CF","year":"2022","unstructured":"Marques CF, Marques MM, Justino GC. Leukotrienes vs. montelukast\u2014activity, metabolism, and toxicity hints for repurposing. Pharmaceuticals (Basel). 2022, 15:1039. 10.3390\/ph15091039","journal-title":"Pharmaceuticals (Basel)"},{"key":"ref15","article-title":"Cromolyn Sodium","author":"Minutello K","year":"2025","unstructured":"Minutello K, Gupta V. Cromolyn Sodium. StatPearls Publishing, Treasure Island, FL; 2025."},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.3390\/nu10070907","article-title":"Betaine improves intestinal functions by enhancing digestive enzymes, ameliorating intestinal morphology, and enriching intestinal microbiota in high-salt stressed rats","volume":"10","author":"Wang H","year":"2018","unstructured":"Wang H, Li S, Fang S, Yang X, Feng J. Betaine improves intestinal functions by enhancing digestive enzymes, ameliorating intestinal morphology, and enriching intestinal microbiota in high-salt stressed rats. Nutrients. 2018, 10:907. 10.3390\/nu10070907","journal-title":"Nutrients"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1002\/eji.200425778","article-title":"In vivo quercitrin anti-inflammatory effect involves release of quercetin, which inhibits inflammation through down-regulation of the NF-kappaB pathway","volume":"35","author":"Comalada M","year":"2005","unstructured":"Comalada M, Camuesco D, Sierra S, Ballester I, Xaus J, G\u00e1lvez J, Zarzuelo A. In vivo quercitrin anti-inflammatory effect involves release of quercetin, which inhibits inflammation through down-regulation of the NF-kappaB pathway. Eur J Immunol. 2005, 35:584-92. 10.1002\/eji.200425778","journal-title":"Eur J Immunol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1093\/ajcn\/81.1.230S","article-title":"Bioavailability and bioefficacy of polyphenols in humans. I. Review of 97 bioavailability studies","volume":"81","author":"Manach C","year":"2005","unstructured":"Manach C, Williamson G, Morand C, Scalbert A, R\u00e9m\u00e9sy C. Bioavailability and bioefficacy of polyphenols in humans. I. Review of 97 bioavailability studies. Am J Clin Nutr. 2005, 81:230S-42S. 10.1093\/ajcn\/81.1.230S","journal-title":"Am J Clin Nutr"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1111\/j.1742-7843.2005.pto960202.x","article-title":"Gastric juice: a barrier against infectious diseases","volume":"96","author":"Martinsen TC","year":"2005","unstructured":"Martinsen TC, Bergh K, Waldum HL. Gastric juice: a barrier against infectious diseases. Basic Clin Pharmacol Toxicol. 2005, 96:94-102. 10.1111\/j.1742-7843.2005.pto960202.x","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1016\/j.chembiol.2006.04.009","article-title":"Rational design of combination enzyme therapy for celiac sprue","volume":"13","author":"Siegel M","year":"2006","unstructured":"Siegel M, Bethune MT, Gass J, et al.. Rational design of combination enzyme therapy for celiac sprue. Chem Biol. 2006, 13:649-58. 10.1016\/j.chembiol.2006.04.009","journal-title":"Chem Biol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/372603-a-case-of-complex-regional-pain-syndrome-with-hypermobile-ehlers-danlos-syndrome-and-mast-cell-activation-syndrome-the-role-of-unconventional-therapies","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,14]],"date-time":"2025-07-14T14:24:23Z","timestamp":1752503063000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/372603-a-case-of-complex-regional-pain-syndrome-with-hypermobile-ehlers-danlos-syndrome-and-mast-cell-activation-syndrome-the-role-of-unconventional-therapies"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,14]]},"references-count":20,"URL":"https:\/\/doi.org\/10.7759\/cureus.87898","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7,14]]}}}